Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elevated levels of C-reactive protein (CRP) are associated with increased risks of ischemic heart disease and ischemic cerebrovascular disease. We tested whether this is a causal association. METHODS: We studied 10,276 persons from a general population cohort, including 1786 in whom ischemic heart disease developed and 741 in whom ischemic cerebrovascular disease developed. We examined another 31,992 persons from a cross-sectional general population study, of whom 2521 had ischemic heart disease and 1483 had ischemic cerebrovascular disease. Finally, we compared 2238 patients with ischemic heart disease with 4474 control subjects and 612 patients with ischemic cerebrovascular disease with 1224 control subjects. We measured levels of high-sensitivity CRP and conducted genotyping for four CRP polymorphisms and two apolipoprotein E polymorphisms. RESULTS: The risk of ischemic heart disease and ischemic cerebrovascular disease was increased by a factor of 1.6 and 1.3, respectively, in persons who had CRP levels above 3 mg per liter, as compared with persons who had CRP levels below 1 mg per liter. Genotype combinations of the four CRP polymorphisms were associated with an increase in CRP levels of up to 64%, resulting in a theoretically predicted increased risk of up to 32% for ischemic heart disease and up to 25% for ischemic cerebrovascular disease. However, these genotype combinations were not associated with an increased risk of ischemic vascular disease. In contrast, apolipoprotein E genotypes were associated with both elevated cholesterol levels and an increased risk of ischemic heart disease. CONCLUSIONS: Polymorphisms in the CRP gene are associated with marked increases in CRP levels and thus with a theoretically predicted increase in the risk of ischemic vascular disease. However, these polymorphisms are not in themselves associated with an increased risk of ischemic vascular disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional biomarkers, including apo B, lipoprotein(a), high-sensitivity C-reactive protein (CRP), coronary artery calcification score, and ankle-brachial index, are independent risk factors associated with increased risk of ASCVD events and may be helpful when the lipid management goal is unclear.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [284]
In the citing paper
“The value of hsCRP as a CV risk factor appears similar to that of conventional CV risk factors – hsCRP is not a causal factor for CV disease and serves as a biomarker only [36].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [36]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“Yet, despite the high CV morbidity and mortality risk, PAD patients are usually inadequately managed compared with CAD patients [511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationFasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Mendelian randomization: prospects, potentials, and limitations
Smith, G. D. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh132 · Cited by 1,222
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877
Cited by
Items 301–400 of 840
Haase, C. L., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003063 · Cited by 37
Self-citationRolver, M. G., Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02207-0 · Cited by 42
Self-citationEltoft, A., Arntzen, K. A., Hansen, J., Wilsgaard, T., Mathiesen, E. B., & Johnsen, S. H. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.07.001 · Cited by 44
Lee, J., Dahl, M., Grande, P., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2009) · Stroke · doi:10.1161/strokeaha.109.567768 · Cited by 37
Self-citationC-reactive protein and disease outcome in Nigerian sickle cell disease patients
Okocha, C., Manafa, P., Ozomba, J., Ulasi, T., Chukwuma, G., & Aneke, J. C. (2014) · Annals of Medical and Health Sciences Research · doi:10.4103/2141-9248.141523 · Cited by 37
Hypertension, Obesity, and Inflammation: The Complex Designs of a Deadly Trio
Rizvi, A. A. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2009.0116 · Cited by 41
Ma, J., & Chen, X. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.631398 · Cited by 41
“Although lowering CRP levels can improve outcomes in patients with coronary heart disease (41), genetic polymorphisms in CRP in the population are not significantly associated with disease risk of ischemic vascular disease (36), and researchers consider CRP itself is unlikely to provide an effective target for interve…”
BackgroundC-Reactive Protein: The Most Familiar Stranger
Ji, S., Zhang, S.-H., Chang, Y., Li, H., Wang, M., Lv, J., Zhu, L., Tang, P. M., & Wu, Y. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200831 · Cited by 37
C-reactive protein and cardiovascular diseases: a synthesis of studies based on different designs
Liu, C., & Li, C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad116 · Cited by 42
Primary Prevention of Cardiovascular Disease: Time to Get More or Less Personal?
Hingorani, A. D., & Psaty, B. M. (2009) · JAMA · doi:10.1001/jama.2009.1698 · Cited by 36
ABC Transporter Genes and Risk of Type 2 Diabetes
Schou, J., Tybjærg‐Hansen, A., Møller, H. J., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2012) · Diabetes Care · doi:10.2337/dc12-0082 · Cited by 38
Self-citationΚίτσιος, Κ., Papadopoulou, M. T., Konstantina, K. P. P., Kadoglou, N. P. E., Papagianni, M., & Tsiroukidou, K. (2013) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.789 · Cited by 45
Ewers, B., Marott, J. L., Schnohr, P., Nordestgaard, B. G., & Marckmann, P. (2021) · European Journal of Preventive Cardiology · doi:10.1177/2047487320937491 · Cited by 35
Self-citationGenetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease
Elliott, P. (2009) · JAMA · doi:10.1001/jama.2009.954 · Cited by 35
“The present study follows a number of smaller inconclusive but consistent studies [6–8].”
Miwa, K., Tanaka, M. R., Okazaki, S., Furukado, S., Sakaguchi, M., Mochizuki, H., & Kitagawa, K. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300350 · Cited by 39
Mattsson, N., Magnussen, C. G., Rönnemaa, T., Mallat, Z., Bénessiano, J., Jula, A., Taittonen, L. M., Kähönen, M. A. P., Juonala, M., Viikari, J. S. A., et al. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.204669 · Cited by 40
The Role and Clinical Significance of High-Sensitivity C-Reactive Protein in Cardiovascular Disease
Seo, H. S. (2012) · Korean Circulation Journal · doi:10.4070/kcj.2012.42.3.151 · Cited by 35
Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction
Hedegaard, A., Ripa, R. S., Johansen, J. S., Jørgensen, E. O., & Kastrup, J. (2010) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365510903518191 · Cited by 35
C-Reactive Protein Levels and Post-ICU Mortality in Nonsurgical Intensive Care Patients
Grander, W., Dünser, M. W., Stollenwerk, B., Siebert, U., Dengg, C., Koller, B., Eller, P., & Tilg, H. (2010) · CHEST Journal · doi:10.1378/chest.09-1677 · Cited by 35
Sicras‐Mainar, A., Rejas, J., Navarro‐Artieda, R., & Blanca-Tamayo, M. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.07.003 · Cited by 44
Christen, T., Trompet, S., Rensen, P. C. N., van Dijk, K. W., Lamb, H. J., Jukema, J. W., Rosendaal, F. R., le Cessie, S., & de Mutsert, R. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.03.010 · Cited by 38
Chen, Y., Ju, H., Xie, K., & Zhao, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410871 · Cited by 44
Biomarkers of Coronary Artery Disease: The Promise of the Transcriptome
Siemelink, M. A., & Zeller, T. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0513-4 · Cited by 35
Atherosclerosis: Recent trials, new targets and future directions
Ladeiras‐Lopes, R., Agewall, S., Tawakol, A. A., Staels, B., Stein, E. A., Mentz, R. J., Leite-Moreira, A. F., Zannad, F. M., & Köenig, W. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.013 · Cited by 39
Sharma, P., & Bentley, P. (2010) · Circulation Research · doi:10.1161/circresaha.110.217992 · Cited by 34
Andreassen, M., Frystyk, J., Faber, J., & Kristensen, L. O. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1009 · Cited by 33
Bækvad‐Hansen, M., Dahl, M., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0963oc · Cited by 33
Self-citationThe CRP genotype, serum levels and lung function in men: the Caerphilly Prospective Study
Bolton, C. E., Schumacher, W., Cockcroft, J. R., Timpson, N. J., Smith, G. D., Gallacher, J., Rumley, A., Lowe, G. D. O., Ebrahim, S. B. J., Shale, D. J., et al. (2010) · Clinical Science · doi:10.1042/cs20100504 · Cited by 34
Stender, S., Frikke‐Schmidt, R., Benn, M., Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.013 · Cited by 38
Self-citationvan Wijk, D. F., Boekholdt, S. M., Arsenault, B. J., Ahmadi‐Abhari, S., Wareham, N. J., Stroes, E. S. G., & Khaw, K. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002823 · Cited by 36
Knudsen, A. D., Gelpi, M., Afzal, S., Ronit, A., Roen, A. O., Mocroft, A., Lundgren, J. D., Nordestgaard, B. G., Sillesen, H. H., Lebech, A., et al. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001795 · Cited by 33
Self-citationRoumeliotis, S. K., Veljkovic, A., Georgianos, P. I., Lazarević, G., Perišić, Z., Hadži-Djokić, J., Liakopoulos, V., & Kocic, G. M. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3090120 · Cited by 43
Ahn, J., Tantry, U. S., Kang, M. G., Park, H. W., Koh, J., Bae, J. S., Cho, S. Y., Kim, K., Jang, J. Y., Park, J. R., et al. (2022) · JACC Asia · doi:10.1016/j.jacasi.2021.11.014 · Cited by 36
“S ystemic and vascular inflammation plays crucial biological roles in the progression and destabilization of atherosclerosis, occurrence of atherothrombotic events,(1) and long-term clinical outcomes.(2,3) Numerous clinical and experimental evidences have supported usefulness of high-sensitivity C-reactive protein (hs…”
BackgroundHeterozygosity for R1141X in ABCC6 and Risk of Ischemic Vascular Disease
Hornstrup, L. S., Tybjærg‐Hansen, A., Haase, C. L., Nordestgaard, B. G., Sillesen, H. H., Grande, P., & Frikke‐Schmidt, R. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.110.958801 · Cited by 33
Self-citationClinical relevance for lowering C-reactive protein with statins
Arévalo‐Lorido, J. C. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1197413 · Cited by 33
Smit, R. A. J., Trompet, S., de Craen, A. J. M., & Jukema, J. W. (2014) · Netherlands Heart Journal · doi:10.1007/s12471-014-0534-z · Cited by 37
Kawase Ishihara, K., Kokubo, Y., Yokota, C., Hida, E., Miyata, T., Toyoda, K., Matsumoto, M., Minematsu, K., & Miyamoto, Y. (2015) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2015.06.039 · Cited by 32
C-Reactive Protein and Markers for Thrombophilia in Patients with Chronic Plaque Psoriasis
Gisondi, P., Malerba, M., Malara, G., Guerra, A. P., Sala, R., Radaeli, A., Calzavara‐Pinton, P., & Girolomoni, G. (2010) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201002300423 · Cited by 35
C reactive protein and long-term risk for chronic kidney disease: a historical prospective study
Kugler, E., Cohen, E., Goldberg, E., Nardi, Y., Levi, A., Krause, I., Garty, M., & Krause, I. (2014) · Journal of Nephrology · doi:10.1007/s40620-014-0116-6 · Cited by 33
Risk Factors for Near-Term Myocardial Infarction in Apparently Healthy Men and Women
Nordestgaard, B. G., Adourian, A. S., Freiberg, J., Guo, Y. F., Muntendam, P., & Falk, E. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.139964 · Cited by 38
Self-citationBhatraju, P. K., Cohen, M., Nagao, R. J., Morrell, E. D., Harju-Baker, S., Chai, X.-Y., Nance, R. M., Dmyterko, V., Delaney, J. A., Christie, J. D., et al. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01935-1 · Cited by 32
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Goicoechea, M., Quiroga, B., de Vinuesa, S. G., Verdalles, Ú., Reque, J., Panizo, N., Arroyo, D., Santos, A., Macías, N., & Luño, J. (2012) · Renal Failure · doi:10.3109/0886022x.2012.696469 · Cited by 32
Genomics and Cardiovascular Drug Development
Plump, A. S., & Lum, P. Y. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.050 · Cited by 31
Cardiac Autonomic Testing and Treating Heart Disease. “A Clinical Perspective”
DePace, N. L., Mears, J. P., Yayac, M. F., & Colombo, J. (2014) · Heart International · doi:10.5301/heartint.5000216 · Cited by 31
Sardo, M. A., Mandraffino, G., Campo, S., Saitta, C., Bitto, A., Alibrandi, A., Riggio, S., Imbalzano, E., & Saitta, A. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.05.024 · Cited by 33
C-reactive protein levels associated with COVID-19 outcomes in the United States
Lentner, J., Adams, T., Knutson, V., Zeien, S., Abbas, H., Moosavi, R. S., Manuel, C., Wallace, T. W., Harmon, A., Waters, R., et al. (2021) · Journal of Osteopathic Medicine · doi:10.1515/jom-2021-0103 · Cited by 31
Wang, Y., Bian, Z.-M., Yu, W., Yan, Z., Chen, W., & Li, X. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.02.008 · Cited by 33
Kurt, B., Rex, K., Reugels, M., Fordyce, C. B., Fudim, M., Sharma, A., Berger, M., Marx, N., Marx-Schütt, K., & Kahles, F. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00710-3 · Cited by 36
Su, H., Zhou, H., Wang, M., Cheng, J., Zhang, S., Feng, H., Chen, X., Liu, S., Liu, Q.-J., Zhu, Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102418 · Cited by 31
Hioki, H., Watanabe, Y., Kozuma, K., Yamamoto, M., Naganuma, T., Araki, M., Tada, N., Shirai, S., Yamanaka, F., Higashimori, A., et al. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.04.005 · Cited by 30
Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
Hu, Q., Hao, P., Liu, Q., Dong, M., Gong, Y., Zhang, C., & Zhang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9537-4 · Cited by 32
Kirkegaard-Klitbo, D. M., Fuchs, A., Stender, S., Sigvardsen, P. E., Kühl, J. T., Kofoed, K. F., Køber, L., Nordestgaard, B. G., Bendtsen, F., Mocroft, A., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa246 · Cited by 32
Self-citationElías-López, D., Doi, T., Nordestgaard, B. G., & Kobylecki, C. J. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000999 · Cited by 40
Self-citationC-Reactive Protein and Genetic Variants and Cognitive Decline in Old Age: The PROSPER Study
Mooijaart, S. P., Sattar, N., Trompet, S., Polisecki, E., de Craen, A. J. M., Schaefer, E. J., Jahn, S. E., van Himbergen, T., Welsh, P., Ford, I., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023890 · Cited by 29
Toth, P. P., McCullough, P. A., Wegner, M. S., & Colley, K. J. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.18 · Cited by 29
Estimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?
Annink, M. E., Kraaijenhof, J. M., Beverloo, C. Y. Y., Oostveen, R. F., Verberne, H. J., Stroes, E. S. G., & Nurmohamed, N. S. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae314 · Cited by 35
Cardiovascular biomarkers for risk stratification in primary prevention
Neumann, F., de Lemos, J. A., Apple, F. S., & Leong, D. P. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf517 · Cited by 32
Cardiac Autonomic Testing and Diagnosing Heart Disease. “A Clinical Perspective”
DePace, N. L., Mears, J. P., Yayac, M. F., & Colombo, J. (2014) · Heart International · doi:10.5301/heartint.5000218 · Cited by 33
Lewis, S. J. (2010) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.109.880955 · Cited by 29
Shah, S. H., & de Lemos, J. A. (2009) · JAMA · doi:10.1001/jama.2009.949 · Cited by 32
Pedersen, K. M., Çolak, Y., Ellervik, C., Hasselbalch, H. C., Bojesen, S. E., & Nordestgaard, B. G. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100280 · Cited by 29
“The four genetic variants were combined and ranked according to the nine most common combinations with increasing concentrations of C-reactive protein [19].”
BackgroundMethodSelf-citationNordestgaard, L. T., Tybjærg‐Hansen, A., Frikke‐Schmidt, R., & Nordestgaard, B. G. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab095 · Cited by 29
Self-citationAhmed, S. K., Mahmood, N., Malalla, Z. H. A., Alsobyani, F. M., Alkiyumi, I. S., & Almawi, W. Y. (2015) · Gene · doi:10.1016/j.gene.2015.05.052 · Cited by 28
C-reactive protein levels in stable COPD patients: a case-control study
Silva, D. R., Knorst, M. M., & Gazzana, M. B. (2015) · International Journal of COPD · doi:10.2147/copd.s87015 · Cited by 29
Mendelian randomization: Its impact on cardiovascular disease
Kawashiri, M., Tada, H., Nomura, A., & Yamagishi, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.04.007 · Cited by 29
Brown, K., Roux, A. V. D., Smith, J. A., Needham, B. L., Mukherjee, B., Ware, E. B., Liu, Y., Cole, S. W., Seeman, T. E., & Kardia, S. L. R. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104654 · Cited by 29
“3 times the risk of cerebrovascular disease compared to those with low levels (Zacho et al., 2008).”
BackgroundHarsløf, M., Pedersen, K. M., Nordestgaard, B. G., & Afzal, S. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314983 · Cited by 30
Self-citationRaaz, D., i, M. H., Ekici, A. B., Klinghammer, L., Lausen, B., Voll, R. E., Leusen, J. H. W., van de Winkel, J. G. J., Daniel, W. G., Reis, A., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.013 · Cited by 27
Genetic risk factors of atherothrombosis
Montagnana, M., Danese, E., & Lippi, G. (2014) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.2409 · Cited by 28
Possible Association of APOE Genotype with Working Memory in Young Adults
Sinclair, L. I., Button, K. S., Munafo, M. R., Day, I. N. M., & Lewis, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135894 · Cited by 29
Costello‐Boerrigter, L. C., Boerrigter, G., Ameenuddin, S., Mahoney, D. W., Slusser, J. P., Heublein, D. M., Redfield, M. M., Rodeheffer, R. J., Olson, T. M., & Burnett, J. C. J. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0708 · Cited by 26
Interrelatedness between C-reactive protein and oxidized low-density lipoprotein
Obradovic, M. M., Trpković, A., Bajić, V., Šoškić, S., Jovanović, A., Stanimirović, J., Panić, M., & Isenović, E. R. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0590 · Cited by 30
Ørsted, D. D., Bojesen, S. E., Kamstrup, P. R., & Nordestgaard, B. G. (2013) · European Urology · doi:10.1016/j.eururo.2013.01.028 · Cited by 26
Self-citationHuang, C., Hsieh, M., Yang, J., Chen, W.-C., Yeh, M., Huang, C.-I., Dai, C., Yu, M., Lin, Z., Chen, S., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9200-8 · Cited by 31
“In addition, the proportion of CHC patients with hs-CRP level [ 3 mg/L, a condition indicative of a high cardiovascular risk, was also higher than healthy controls [14].”
BackgroundC‐reactive Protein: Repeated Measurements will Improve Dialysis Patient Care
Cobo, G., Qureshi, A. R., Lindholm, B., & Stenvinkel, P. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12440 · Cited by 28
Advancing Cardiovascular Research
Lauer, M. S. (2012) · CHEST Journal · doi:10.1378/chest.11-2521 · Cited by 29
FACEing reality: productive tensions between our epidemiological questions, methods and mission
Krieger, N., & Smith, G. D. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw330 · Cited by 26
Nordestgaard, L. T., Tybjærg‐Hansen, A., Rasmussen, K. L., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2018) · BMC Medicine · doi:10.1186/s12916-018-1029-3 · Cited by 27
Self-citationLi, X., Peng, S., Guan, B., Chen, S., Zhou, G., Wei, Y. Q., Gong, C., Xu, J., Lu, X., Zhang, X., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.734400 · Cited by 27
“Previous MR studies have indicated that CRP was unlikely to be a causal factor for ischemic cardiovascular disease (42), and there was only very weak evidence of a causal effect of fibrinogen on coronary heart disease (CHD) (43).”
BackgroundRothenbacher, D., Kleiner, A., Köenig, W., Primatesta, P., Breitling, L. P., & Brenner, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045907 · Cited by 28
Emerging inflammatory markers for assessing coronary heart disease risk
Corson, M. A. (2009) · Current Cardiology Reports · doi:10.1007/s11886-009-0065-1 · Cited by 26
Systemic inflammation and early atheroma formation: are they related?
Balanescu, S. M., Câlmâc, L., Constantinescu, D., Marinescu, M., Onuţ, R., & Dorobanţu, M. (2010) · Europe PMC (PubMed Central) · Cited by 25
Ahluwalia, T. S., Allin, K. H., Sandholt, C. H., Sparsø, T., Jørgensen, M. E., Rowe, M. W., Christensen, C., Brandslund, I., Lauritzen, T., Linneberg, A. R., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3677 · Cited by 26
Should We Measure C‐reactive Protein on Earth or Just on JUPITER?
Bajpai, A., Goyal, A., & Sperling, L. S. (2010) · Clinical Cardiology · doi:10.1002/clc.20681 · Cited by 27
Regulation of cell function by isoforms of C-reactive protein: a comparative analysis.
Boncler, M. A., & Watała, C. W. (2009) · Acta Biochimica Polonica · doi:10.18388/abp.2009_2513 · Cited by 27
Kelly, C. R., Weisz, G., Maehara, A., Mintz, G. S., Mehran, R., Lansky, A. J., Parise, H., Bruyne, B. D., Serruys, P. W. J. C., & Stone, G. W. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.04.048 · Cited by 24
Actualización en cardiopatía isquémica
Bardají, A., Barrabés, J. A., Sanchis, J. M., & Sanchez, P. L. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70140-8 · Cited by 27
Mendelian Randomization and the Environmental Epigenetics of Health: a Systematic Review
Grau-Pérez, M., Agha, G., Pang, Y., Bermúdez, J. D., & Téllez-Plaza, M. (2019) · Current Environmental Health Reports · doi:10.1007/s40572-019-0226-3 · Cited by 24
C-Reactive Protein and White Blood Cell Count in Cardiogenic Shock
Dudda, J., Schupp, T., Rusnak, J., Weidner, K., Abumayyaleh, M., Ruka, M., Egner-Walter, S., Forner, J., Müller, J., Bertsch, T., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030965 · Cited by 24
“Finally, CRP gene polymorphisms were shown to be associated with a marked increase in CRP and could therefore be confounders of our results [54].”
ResultAssociation of C-reactive Protein Gene Polymorphisms and Colorectal Cancer
Yang, S.-H., Huang, C., Chang, S., & Lin, J.-K. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1575-9 · Cited by 25
Nührenberg, T. G., Langwieser, N. N., Binder, H., Kurz, T., Stratz, C., Kienzle, R.-P., Trenk, D., Zohlnhöfer-Momm, D., & Neumann, F. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9420-5 · Cited by 25
Kaur‐Knudsen, D., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Bojesen, S. E. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833042cb · Cited by 24
Self-citationZhang, Z., Yang, Y., Hill, M. A., & Wu, J. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00433 · Cited by 26
Kjaergaard, A. D., Bojesen, S. E., Nordestgaard, B. G., & Johansen, J. S. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.229096 · Cited by 25
Self-citationSystemic inflammation is associated with incident stroke and heart disease in East Asians
Karim, M. A., Kartsonaki, C., Bennett, D., Millwood, I. Y., Hill, M., Avery, D., Bian, Z., Du, H., Guo, Y., Qian, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-62391-3 · Cited by 28
Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
Torzewski, J., Brunner, P., Ries, W., Garlichs, C. D., Kayser, S., Heigl, F., & Sheriff, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071771 · Cited by 26
Using Mendelian randomization to determine causative factors in cardiovascular disease
Johansen, C. T., & Hegele, R. A. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02586.x · Cited by 24
Jaleel, A., Klaus, K. A., Morse, D. M., Karakelides, H., Ward, L. E., Irving, B. A., & Nair, K. S. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00351.2009 · Cited by 23
Lipid profile and statin use in critical care setting: implications for kidney outcome
Malbouisson, I., Quinto, B. M. R., Durão, M. D. S., Monte, J. C. M., dos Santos, O. F. P., Narciso, R. C., Dalboni, M. A., & Batista, M. C. (2019) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2019ao4399 · Cited by 25
“, demonstrated that in patients with sepsis using rosuvastatin as the reference, atorvastatin and simvastatin had superior efficacy in preventing mortality.(22-30) Additionally, Craig et al.”
Background
Metadata
- Authors
- Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Rigshospitalet (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-30
- Volume
- 359
- Issue
- 18
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081615427
- Cited by
- 839
- References
- 36
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 21 · 2023: 21 · 2022: 26 · 2021: 25 · 2020: 33 · 2019: 25 · 2018: 28 · 2017: 40 · 2016: 48 · 2015: 44 · 2014: 61 · 2013: 56 · 2012: 76
- FWCI
- 102.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Keywords
- C-reactive protein, ischemic heart disease, ischemic cerebrovascular disease, ischemic vascular disease, CRP gene polymorphisms, apolipoprotein E, high-sensitivity CRP, genetic association, cholesterol levels, causal relationship
- MeSH terms
- C-Reactive Protein, Cerebrovascular Disorders, Cross-Sectional Studies, Female, Humans, Male, Polymorphism, Genetic, Risk Factors, Cohort Studies, Biomarkers, Myocardial Ischemia, Genetic Predisposition to Disease, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.